Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
Portfolio Pulse from Benzinga Newsdesk
Reshape Lifesciences (NASDAQ:RSLS) reported FY23 sales of $8.678M, missing the analyst consensus estimate of $8.904M by 2.54%.
April 01, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reshape Lifesciences reported FY23 sales of $8.678M, missing estimates by 2.54%.
Missing sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. Given the miss was relatively small (2.54%), the impact might be moderate but still negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100